Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy

Progress in Retinal and Eye Research

Volumn 48, Issue , 2015, Pages 40-61

  Kowluru, Renu A ^a   Kowluru, Anjan ^a,b   Mishra, Manish ^a   Kumar, Binit ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetic retinopathy; Epigenetic modifications; Mitochondria; Oxidative stress; Reactive oxygen species; Transcriptional regulation

Indexed keywords

ANTIOXIDANT; FREE RADICAL; MATRIX METALLOPROTEINASE; MICRORNA; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR;

BIOCHEMICAL ANALYSIS; CYTOSOL; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; ELECTRON TRANSPORT; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE CONTROL; HEREDITY; HISTONE MODIFICATION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; MEMBRANE POTENTIAL; METABOLIC DISORDER; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

DIABETIC RETINOPATHY; DISEASE PROGRESSION; DNA DAMAGE; DNA METHYLATION; DNA, MITOCHONDRIAL; EPIGENESIS, GENETIC; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84939260083     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2015.05.001     Document Type: Review

References (229)

1. Abhary S., Hewitt A.W., Burdon K.P., Craig J.E. Asystematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009, 58:2137-2147.
2. Afanas'ev I. New nucleophilic mechanisms of Ros-dependent epigenetic modifications: comparison of aging and cancer. Aging Dis. 2014, 5:52-62.
3. Aiello L.P. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014, 37:17-23.
4. Aiello L.P., Brusell S.E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T.A., Ways K., Jirousek M., Smith L.E.H., King G.L. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C invivo and suppressed by an orally effective beta isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
5. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic retinopathy. Diabetes Care 1998, 21:143-156.
6. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N.Engl. J. Med. 2012, 366:1227-1239.
7. Arar N.H., Freedman B.I., Adler S.G., Iyengar S.K., Chew E.Y., Davis M.D., Satko S.G., Bowden D.W., Duggirala R., Elston R.C., Guo X., Hanson R.L., Igo R.P., Ipp E., Kimmel P.L., Knowler W.C., Molineros J., Nelson R.G., Pahl M.V., Quade S.R., Rasooly R.S., Rotter J.I., Saad M.F., Scavini M., Schelling J.R., Sedor J.R., Shah V.O., Zager P.G., Abboud H.E. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Investig. Ophthalmol. Vis. Sci. 2008, 49:3839-3845.
8. Arnal E., Miranda M., Johnsen-Soriano S., Alvarez-Nölting R., Díaz-Llopis M., Araiz J., Cervera E., Bosch-Morell F., Romero F.J. Beneficial effect of docosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats. Curr. Eye Res. 2009, 34:928-938.
9. Aso Y., Inukai T., Tayama K., Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000, 37:87-92.
10. Bandello F., Battaglia Parodi M., Lanzetta P., Loewenstein A., Massin P., Menchini F., Veritti D. Diabetic macular edema. Dev. Ophthalmol. 2010, 47:73-110.
11. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991, 40:405-412.
12. Bell C.G., Teschendorff A.E., Rakyan V.K., Maxwell A.P., Beck S., Savage D.A. Genome- wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med. Genomics 2010, 3:1-11.
13. Bishop K.S., Ferguson L.R. The interaction between epigenetic, nutrition and the development of cancer. Nutrients 2015, 7:922-947.
14. Bokoch G.M., Zhao T. Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid. Redox Signal. 2006, 8:1533-1548.
15. Bonnefond A., Saulnier P.J., Stathopoulou M.G., Grarup N., Ndiaye N.C., Roussel R., Nezhad M.A., Dechaume A., Lantieri O., Hercberg S., Lauritzen T., Balkau B., El-Sayed Moustafa J.S., Hansen T., Pedersen O., Froguel P., Charpentier G., Marre M., Hadjadj S., Visvikis-Siest S. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications?. PLoS ONE 2013, 8:e55921.
16. Branco M.R., Ficz G., Reik W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat. Rev. Genet. 2011, 13:7-13.
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
18. Bursell S.E., Clermont A.C., Aiello L.P., Aiello L.M., Schlossman D.K., Feener E.P., Laffel L.O.R.L., King G.L. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999, 22:1245-1251.
19. Cao Y., Feng B., Chen S., Chu Y., Chakrabarti S. Mechanisms of endothelial to mesenchymal transition in the retina in diabetes. Investig. Ophthalmol. Vis. Sci. 2014, 55:7321-7331.
20. Caroli A., Cardillo M.T., Galea R., Biasucci L.M. Potential therapeutic role of microRNAs in ischemic heart disease. J.Cardiol. 2013, 61:315-320.
21. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10:295-304.
22. Chen W., Esselman W.J., Jump D.B., Busik J.V. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 2005, 46:4342-4347.
23. Chen X.J., Butow R.A. The organization and inheritance of the mitochondrial genome. Nat. Rev. Genet. 2005, 6:815-825.
24. Chen Z., Shentu T.P., Wen L., Johnson D.A., Shyy J.Y. Regulation of SIRT1 by oxidative stress-responsive miRNAs and a systematic approach to identify its role in the endothelium. Antioxid. Redox Signal. 2013, 19:1522-1538.
25. Chervona Y., Costa M. The control of histone methylation and gene expression by oxidative stress, hypoxia, and metals. Free Radic. Biol. Med. 2012, 53:1047.
26. Chestnut B.A., Chang Q., Price A., Lesuisse C., Wong M., Martin L.J. Epigenetic regulation of motor neuron cell death through DNA methylation. J.Neurosci. 2011, 31:16619-16636.
27. Chew E.Y., Davis M.D., Danis R.P., Lovato J.F., Perdue L.H., Greven C., Genuth S., Goff D.C., Leiter L.A., Ismail-Beigi F., Ambrosius W.T. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014, 121:2443-2451.
28. Choi K.C., Jung M.G., Lee Y.H., Yoon J.C., Kwon S.H., Kang H.B., Kim M.J., Cha J.H., Kim Y.J., Jun W.J., Lee J.M., Yoon H.G. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009, 69:583-592.
29. Chous A., Richer S., Kowluru R.A., Gerson J. The Diabetes Visual Function Supplement Study (DiVFuSS). Br. J. Ophthalmol. 2015, (in press).
30. Christ S.L., Zheng D.D., Swenor B.K., Lam B.L., West S.K., Tannenbaum S.L., Munoz B.E., Lee D.J. Longitudinal relationships among visual acuity, daily functional status, and mortality: the Salisbury Eye Evaluation Study. JAMA Ophthalmol. 2014, 132:1400-1406.
31. Clayton D.A. Transcription and replication of mitochondrial DNA. Hum. Reprod. 2000, 15:11-17.
32. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., Salvemini D., Yorek M.A. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br. J. Pharmacol. 2001, 134:21-29.
33. Curtis T.M., Hamilton R., Yong P.H., McVicar C.M., Berner A., Pringle R., Uchida K., Nagai R., Brockbank S., Stitt A.W. Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 2011, 54:690-698.
34. Cutler R.G. Oxidative stress profiling: part I. Its potential importance in the optimization of human health. Ann. N. Y. Acad. Sci. 2005, 1055:93-135.
35. Dagher Z., Park Y.S., Asnaghi V., Hoehn T., Gerhardinger C., Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004, 53:2404-2411.
36. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim. Biophys. Acta 2010, 1797:897-906.
37. Davis M.D., Sheetz M.J., Aiello L.P., Milton R.C., Danis R.P., Zhi X., Girach A., Jimenez M.C., Vignati L. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Investig. Ophthalmol. Vis. Sci. 2009, 50:1-4. PKC-DRS2 Study Group.
38. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25:1010-1022.
39. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N.Engl. J. Med. 1993, 329:977-986.
40. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N.Engl. J. Med. 2005, 353:2643-2653.
41. Druz A., Betenbaugh M., Shiloach J. Glucose depletion activates mmu-miR-466h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Res. 2012, 40:7291-7302.
42. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengeller Z., Szabo C., Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J.Clin. Investig. 2003, 112:1049-1057.
43. Du X.L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., Wu J., Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. 2000, 97:12222-12226.
44. Duarte F.V., Palmeira C.M., Rolo A.P. The role of microRNAs in mitochondria: small players acting wide. Genes 2014, 5:865-886.
45. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 2003, 4:457-467.
46. Dzitoyeva S., Chen H., Manev H. Effect of aging on 5-hydroxymethylcytosine in brain mitochondria. Neurobiol. Aging 2012, 33:2881-2891.
47. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., Cooper M.E., Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J.Exp. Med. 2008, 205:2409-2417.
48. Engerman R.L., Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
49. Fahrner J.A., Eguchi S., Herman J.G., Baylin S.B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002, 62:7213-7218.
50. Feng B., Ruiz M.A., Chakrabarti S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications. Can. J. Physiol. Pharmacol. 2013, 91:213-220.
51. Frank R.N. Diabetic retinopathy. N.Engl. J. Med. 2004, 350:48-58.
52. Frey R.S., Ushio-Fukai M., Malik A.B. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid. Redox Signal. 2009, 11:791-810.
53. Fu D., Yu J.Y., Wu M., Du M., Chen Y., Abdelsamie S.A., Li Y., Chen J., Boulton M.E., Ma J.X., Lopes-Virella M.F., Virella G., Lyons T.J. Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes. J.Lipid Res. 2014, 55:860-869.
54. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
55. Garay R.P., Hannaert P., Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat. Endocrinol. 2005, 4:221-232.
56. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60:167-179.
57. Gemenetzi M., Lotery A.J. The role of epigenetics in age-related macular degeneration. Eye (Lond.) 2014, 28:1407-1417.
58. Genuth S., Sun W., Cleary P., Gao X., Sell D.R., Lachin J., Monnier V.M. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 2015, 64:266-278.
59. Geraldes P., Hiraoka-Yamamoto J., Matsumoto M., Clermont A., Leitges M., Marette A., Aiello L.P., Kern T.S., King G.L. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med. 2009, 15:1298-1306.
60. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
61. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996, 19:257-267.
62. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26:5420-5432.
63. Grassi M.A., Tikhomirov A., Ramalingam S., Lee K.E., Hosseini S.M., Klein B.E., Klein R., Lussier Y.A., Cox N.J., Nicolae D.L. Replication analysis for severe diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2012, 53:2377-2381.
64. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9:294-299.
65. Iacobazzi V., Castegna A., Infantino V., Andria G. Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol. Genet. Metab. 2013, 110:25-34.
66. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J. Biol. Chem. 2010, 1:209-220.
67. Kadiyala C.S., Zheng L., Du Y., Yohannes E., Kao H.Y., Miyagi M., Kern T.S. Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J.Biol. Chem. 2012, 287:25869-25880.
68. Kador P.F., Akagi Y., Takahashi Y., Ikebe H., Wyman M., Kinoshita J.H. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch. Ophthalmol. 1990, 108:1301-1309.
69. Kanwar M., Chan P.S., Kern T.S., Kowluru R.A. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Investig. Ophthalmol. Vis. Sci. 2007, 48:3805-3811.
70. Kanwar M., Kowluru R. Role of glyceraldehyde 3-phosphate dehydrogenase in the development and progression of diabetic retinopathy. Diabetes 2009, 58:227-234.
71. Katakami N., Kaneto H., Takahara M., Matsuoka T.A., Imamura K., Ishibashi F., Kanda T., Kawai K., Osonoi T., Matsuhisa M., Kashiwagi A., Kawamori R., Shimomura I., Yamasaki Y. Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2011, 92:e57-60.
72. Kato M., Natarajan R. Diabetic nephropathy-emerging epigenetic mechanisms. Nat. Rev. Nephrol. 2014, 10:517-530.
73. Kazak L., Reyes A., Holt I.J. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat. Rev. Mol. Cell Biol. 2012, 13:659-671.
74. Kearney F.M., Fagan X.J., Al-Qureshi S. Review of the role of refined dietary sugars (fructose and glucose) in the genesis of retinal disease. Clin. Exp. Ophthalmol. 2014, 42:564-573.
75. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., Taskinen M.R., Simes R.J., Tse D., Williamson E., Merrifield A., Laatikainen L.T., d'Emden M.C., Crimet D.C., O'Connell R.L., Colman P.G. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
76. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:95103.
77. Kern T.S. Interrelationships between the retinal neuroglia and vasculature in diabetes. Diabetes Metab. J. 2014, 38:163-170.
78. Kern T.S., Kowluru R., Engerman R.L. Abnormalities of retinal metabolism in diabetes or galactosemia. ATPases and glutathione. Investig. Ophthalmol. Vis. Sci. 1994, 35:2962-2967.
79. Kern T.S., Tang J., Mizutani M., Kowluru R., Nagraj R., Lorenzi M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Investig. Ophthalmol. Vis. Sci. 2000, 41:3972-3978.
80. Kim J., Hwang J., Jeong H., Song H.J., Shin J., Hur G., Park Y.W., Lee S.H. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics 2012, 7:191-200.
81. Kizawa J., Machida S., Kobayashi T., Gotoh Y., Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn. J. Ophthalmol. 2006, 50:367-373.
82. Kohli R.M., Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013, 502:472-479.
83. Kouzarides T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 2002, 12:198-209.
84. Kowaltowski A.J., de Souza-Pinto N.C., Castilho R.F., Vercesi A.E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med. 2009, 47:333-343.
85. Kowluru A., Kowluru R.A. Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes. Biochem. Pharmacol. 2014, 88:275-283.
86. Kowluru R., Kern T.S., Engerman R.L. Abnormalities of retinal metabolism in diabetes or galactosemia II. Comparison of gamma-glutamyl transpeptidase in retina and cerebral cortex, and effects of antioxidant therapy. Curr. Eye Res. 1994, 13:891-896.
87. Kowluru R.A. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are inter-related. Acta Diabetol. 2001, 38:179-185.
88. Kowluru R.A. Effect of re-institution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003, 52:818-823.
89. Kowluru R.A. Diabetic retinopathy, oxidative stress and antioxidants. Curr. Top. Nutraceutical Res. 2005, 3:209-218.
90. Kowluru R.A. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid. Redox Signal. 2005, 7:1581-1587.
91. Kowluru R.A. Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. Investig. Ophthalmol. Vis. Sci. 2010, 51:4320-4326.
92. Kowluru R.A. Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression. Curr. Med. Chem. 2013, 20:3226-3233.
93. Kowluru R.A., Abbas S.N. Diabetes-induced mitochondrial dysfunction in the retina. Investig. Ophthalmol. Vis. Sci. 2003, 44:5327-5334.
94. Kowluru R.A., Abbas S.N., Odenbach S. Effect of re-institution of good metabolic control on oxidative stress in the kidney of diabetic rats. J.Diabetes Complicat. 2004, 18:282-288.
95. Kowluru R.A., Atasi L., Ho Y.S. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2006, 47:1594-1599.
96. Kowluru R.A., Engerman R.L., Kern T.S. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VI. Comparison of retinal and cerebral cortex metabolism, and effects of antioxidant therapy. Free Radic. Biol. Med. 1999, 26:371-378.
97. Kowluru R.A., Kanwar M. Effect of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr. Metab. (Lond.) 2007, 4:1-8.
98. Kowluru R.A., Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic. Biol. Med. 2009, 46:1677-1685.
99. Kowluru R.A., Kanwar M., Chan P.S., Zhang J.P. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch. Ophthalmol. 2008, 126:1266-1272.
100. Kowluru R.A., Kanwar M., Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp. Diabetes Res. 2007, 2007:2196.
101. Kowluru R.A., Kennedy A. Therapeutic potential of anti-oxidants and diabetic retinopathy. Expert Opin. Investig. Drugs 2001, 10:1665-1676.
102. Kowluru R.A., Kern T.S., Engerman R.L. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant defense system. Free Radic. Biol. Med. 1997, 22:587-592.
103. Kowluru R.A., Kern T.S., Engerman R.L., Armstrong D. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. III. Effects of antioxidants. Diabetes 1996, 45:1233-1237.
104. Kowluru R.A., Kowluru A., Veluthakal R., Mohammad G., Syed I., Santos J.M., Mishra M. TIAM1-RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy. Diabetologia 2014, 57:1047-1056.
105. Kowluru R.A., Kowluru V., Ho Y.S., Xiong Y. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic. Biol. Med. 2006, 41:1191-1196.
106. Kowluru R.A., Menon B., Gierhart D. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rat. Investig. Ophthalmol. Vis. Sci. 2008, 49:1645-1651.
107. Kowluru R.A., Mohammad G., dos Santos J.M., Zhong Q. Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011, 60:3023-3033.
108. Kowluru R.A., Odenbach S. Effect of long-term administration of alpha lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004, 53:3233-3238.
109. Kowluru R.A., Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Investig. Ophthalmol. Vis. Sci. 2004, 45:4161-4166.
110. Kowluru R.A., Santos J.M., Mishra M. Epigenetic modifications and diabetic retinopathy. Biomed. Res. Int. 2013, 2013:635284.
111. Kowluru R.A., Santos J.M., Zhong Q. Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2014, 55:5653-5660.
112. Kowluru R.A., Tang J., Kern T.S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001, 50:1938-1942.
113. Kowluru R.A., Zhong Q., Santos J.M., Thandampallayam M., Putt D., Gierhart D.L. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr. Metab. (Lond.) 2014, 11:8.
114. Kren B.T., Wong P.Y., Sarver A., Zhang X., Zeng Y., Steer C.J. MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol. 2009, 6:65-72.
115. Kubicek S., O'Sullivan R.J., August E.M., Hickey E.R., Zhang Q., Teodoro M.L., Rea S., Mechtler K., Kowalski J.A., Homon C.A., Kelly T.A., Jenuwein T. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 2007, 25:473-481.
116. Lewis K.N., Mele J., Hayes J.D., Buffenstein R. Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr. Comp. Biol. 2010, 50:829-843.
117. Liu B., Bhat M., Padival A.K., Smith D.G., Nagaraj R.H. Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Investig. Ophthalmol. Vis. Sci. 2004, 45:1983-1995.
118. Looker H.C., Nelson R.G., Chew E., Klein R., Klein B.E., Knowler W.C., Hanson R.L. Genome-wide linkage analyses to identify Loci for diabetic retinopathy. Diabetes 2007, 56:1160-1166.
119. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 2007:61038.
120. Lyons T.J., Jenkins A.J., Zheng D., Lackland D.T., McGee D., Garvey W.T., Klein R.L. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Diabetes 2004, 45:910-918.
121. Madsen-Bouterse S.A., Kowluru R.A. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev. Endocr. Metab. Disord. 2008, 9:315-327.
122. Madsen-Bouterse S.A., Mohammad G., Kanwar M., Kowluru R.A. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid. Redox Signal. 2010, 13:797-805.
123. Madsen-Bouterse S.A., Mohammad G., Kowluru R.A. Glyceraldehyde 3 phosphate dehydrogenase in retinal microvasculature: implications for the development and progression of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2010, 51:1765-1772.
124. Madsen-Bouterse S.A., Zhong Q., Mohammad G., Ho Y.S., Kowluru R.A. Oxidative damage of mitochondrial DNA in diabetes, and its protection by manganese superoxide dismutase. Free Radic. Res. 2010, 44:313-321.
125. Maghbooli Z., Hossein-Nezhad A., Larijani B., Amini M., Keshtkar A. Global DNA methylation as a possible biomarker for diabetic retinopathy. Diabetes Metab. Res. Rev. 2015, 31:183-189.
126. Maghbooli Z., Larijani B., Emamgholipour S., Amini M., Keshtkar A., Pasalar P. Aberrant DNA methylation patterns in diabetic nephropathy. J.Diabetes Metab. Disord. 2014, 13:69.
127. Majid S., Dar A.A., Ahmad A.E., Hirata H., Kawakami K., Shahryari V., Saini S., Tanaka Y., Dahiya A.V., Khatri G., Dahiya R. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009, 30:662-670.
128. Majumdar S., Buckles E., Estrada J., Koochekpour S. Aberrant DNA methylation and prostate cancer. Curr. Genomics 2011, 12:486-505.
129. Manev H., Dzitoyeva S., Chen H. Mitochondrial DNA: a blind spot in neuroepigenetics. Biomol. Concepts 2012, 3:107-115.
130. Martin S.A., Lord C.J., Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin. Cancer Res. 2010, 16:5107-5113.
131. Mastropasqua R., Toto L., Cipollone F., Santovito D., Carpineto P., Mastropasqua L. Role of microRNAs in the modulation of diabetic retinopathy. Prog. Retin. Eye Res. 2014, 43C:92-107.
132. Matsushima S., Kuroda J., Ago T., Zhai P., Park J.Y., Xie L.H., Tian B., Sadoshima J. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ. Res. 2013, 112:651-663.
133. Mayer-Davis E.J., Bell R.A., Reboussin B.A., Rushing J., Marshall J.A., Hamman R.F. Antioxidant nutrient intake and diabetic retinopathy: the San Luis Vally diabetes study. Ophthalmology 1998, 105:2264-2270.
134. McArthur K., Feng B., Wu Y., Chen S., Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60:1314-1323.
135. Meier M., King G.L. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc. Med. 2000, 5:173-185.
136. Meister A. Glutathione metabolism and its selective modification. J.Biol. Chem. 1988, 263:17205-17208.
137. Miao F., Chen Z., Genuth S., Paterson A., Zhang L., Wu X., Li S., Cleary P., Riggs A., Harlan D., Lorenzi G., Kolterman O., Sun W., Lachin J., Natarajan R. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 2014, 63:1748-1762.
138. Miao F., Chen Z., Zhang L., Liu Z., Wu X., Yuan Y.C., Natarajan R. Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J.Biol. Chem. 2012, 287:16335-16345.
139. Miao F., Chen Z., Zhang L., Wang J., Gao H., Wu X., Natarajan R. RNA-sequencing analysis of high glucose-treated monocytes reveals novel transcriptome signatures and associated epigenetic profiles. Physiol. Genomics 2013, 45:287-299.
140. Millen A.E., Gruber M., Klein R., Klein B.E., Palta M., Mares J.A. Relations of serum ascorbic acid and alpha-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2003, 158:225-233.
141. Millen A.E., Klein R., Folsom A.R., Stevens J., Palta M., Mares J.A. Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am. J. Clin. Nutr. 2004, 79:865-873.
142. Mishra M., Kowluru R.A. Retinal mitochondrial DNA mismatch repair in the development of diabetic retinopathy, and its continued progression after termination of hyperglycemia. Investig. Ophthalmol. Vis. Sci. 2014, 55:6960-6967.
143. Mishra M., Zhong Q., Kowluru R.A. Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2014, 55:7256-7265.
144. Mishra M., Zhong Q., Kowluru R.A. Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression. Free Radic. Biol. Med. 2014, 75C:129-139.
145. Miyazawa-Hoshimoto S., Takahashi K., Bujo H., Hashimoto N., Saito Y. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003, 46:1483-1488.
146. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J.Clin. Investig. 1996, 97:2883-2890.
147. Mohammad G., Kowluru R.A. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab. Investig. 2010, 90:1365-1372.
148. Mohammad G., Kowluru R.A. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2011, 52:3832-3841.
149. Mohammad G., Kowluru R.A. The role of Raf-1 kinase in diabetic retinopathy. Expert Opin. Ther. Targets 2011, 15:537-564.
150. Moore T.C., Moore J.E., Kaji Y., Frizzell N., Usui T., Poulaki V., Campbell I.L., Stitt A.W., Gardiner T.A., Archer D.B., Adamis A.P. The role of advanced glycation end products in retinal microvascular leukostasis. Investig. Ophthalmol. Vis. Sci. 2003, 44:4457-4464.
151. Murphy M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2009, 417:1-13.
152. Musri M.M., Carmona M.C., Hanzu F.A., Kaliman P., Gomis R., Párrizas M. Histone demethylase LSD1 regulates adipogenesis. J.Biol. Chem. 2010, 285:30034-30041.
153. Mustata G.T., Rosca M., Biemel K.M., Reihl O., Smith M.A., Viswanathan A., Strauch C., Du Y., Tang J., Kern T.S., Lederer M.O., Brownlee M., Weiss M.F., Monnier V.M. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005, 54:517-526.
154. Nakamura M., Barber A.J., Antonetti D.A., LaNoue K.F., Robinson K.A., Buse M.G., Gardner T.W. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J.Biol. Chem. 2001, 47:43748-43755.
155. Narayanan S.P., Rojas M., Suwanpradid J., Toque H.A., Caldwell R.W., Caldwell R.B. Arginase in retinopathy. Prog. Retin. Eye Res. 2013, 36:260-280.
156. Nassar T., Kadery B., Lotan C., Da'as N., Kleinman Y., Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2002, 436:111-118.
157. Nebbioso M., Federici M., Rusciano D., Evangelista M., Pescosolido N. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol. Ther. 2012, 14:257-263.
158. Nightingale K.P., O'Neill L.P., Turner B.M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 2006, 16:125-136.
159. Niu P.P., Cao Y., Gong T., Guo J.H., Zhang B.K., Jia S.J. Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients. J.Transl. Med. 2014, 12:170.
160. Paravicini T.M., Touyz R.M. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008, 31:S170-S180.
161. Perrone L., Devi T.S., Hosoya K.I., Terasaki T., Singh L.P. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J.Cell. Physiol. 2009, 221:262-272.
162. Perrone L., Matrone C., Singh L.P. Epigenetic modifications and potential new treatment targets in diabetic retinopathy. J.Ophthalmol. 2014, 2014:789120.
163. Poirier L.A., Brown A.T., Fink L.M., Wise C.K., Randolph C.J., Delongchamp R.R., Fonseca V.A. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 2001, 50:1014-1018.
164. Qing S., Yuan S., Yun C., Hui H., Mao P., Wen F., Ding Y., Liu Q. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell. Physiol. Biochem. 2014, 34:1733-1740.
165. Raciti G.A., Nigro C., Longo M., Parrillo L., Miele C., Formisano P., Beguinot F. Personalized medicine and type 2 diabetes: lesson from epigenetics. Epigenomics 2014, 6:229-238.
166. Rai K., Jafri I.F., Chidester S., James S.R., Karpf A.R., Cairns B.R., Jones D.A. Dnmt3 and G9a cooperate for tissue-specific development in zebrafish. J.Biol. Chem. 2010, 285:4110-4121.
167. Ramasamy R., Yan S.F., Schmidt A.M. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. N. Y. Acad. Sci. 2011, 1243:88-102.
168. Reddy M.A., Zhang E., Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 2015, 58:443-455.
169. Regha K., Sloane M.A., Huang R., Pauler F.M., Warczok K.E., Melikant B., Radolf M., Martens J.H., Schotta G., Jenuwein T., Barlow D.P. Active and repressive chromatin are interspersed without spreading in an imprinted gene cluster in the mammalian genome. Mol. Cell 2007, 27:353-366.
170. Robinson R., Barathi V.A., Chaurasia S.S., Wong T.Y., Kern T.S. Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals. Dis. Model Mech. 2012, 5:444-456.
171. Romeo G., Liu W.H., Asnaghi V., Kern T.S., Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002, 51:2241-2248.
172. Rothfuss O., Gasser T., Patenge N. Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-time PCR approach. Nucleic Acids Res. 2010, 38:e24.
173. SanGiovanni J.P., Chew E.Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Retin. Eye Res. 2005, 24:87-138.
174. Santos J.M., Kowluru R.A. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Investig. Ophthalmol. Vis. Sci. 2011, 52:8791-8798.
175. Santos J.M., Kowluru R.A. Impaired transport of mitochondrial transcription factor A (TFAM) and the metabolic memory phenomenon associated with the progression of diabetic retinopathy. Diabetes Metab. Res. Rev. 2013, 29:204-213.
176. Santos J.M., Mishra M., Kowluru R.A. Posttranslational modification of mitochondrial transcription factor A in impaired mitochondria biogenesis: implications in diabetic retinopathy and metabolic memory phenomenon. Exp. Eye Res. 2014, 121:168-177.
177. Santos J.M., Mohammad G., Zhong Q., Kowluru R.A. Diabetic retinopathy, superoxide damage and antioxidant. Curr. Pharm. Biotechnol. 2011, 12:352-361.
178. Santos J.M., Tewari S., Goldberg A.F.X., Kowluru R.A. Mitochondria biogenesis and the development of diabetic retinopathy. Free Radic. Biol. Med. 2011, 51:1849-1860.
179. Santos J.M., Tewari S., Kowluru R.A. Acompensatory mechanism protects retinal mitochondria from initial insult in diabetic retinopathy. Free Radic. Biol. Med. 2012, 53:1729-1737.
180. Santos J.M., Tewari S., Lin J.Y., Kowluru R.A. Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochem. Biophys. Res. Commun. 2013, 438:760-764.
181. Santos R.X., Correia S.C., Zhu X., Smith M.A., Moreira P.I., Castellani R.J., Nunomura A., Perry G. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid. Redox Signal. 2013, 18:2444-2457.
182. Sarkar S., Goldgar S., Byler S., Rosenthal S., Heerboth S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 2013, 5:87-94.
183. Scarpulla R.C. Nucleus-encoded regulators of mitochondrial function: integration of respiratory chain expression, nutrient sensing and metabolic stress. Biochim. Biophys. Acta 2012, 1819:1088-1097.
184. Shock L.S., Thakkar P.V., Peterson E.J., Moran R.G., Taylor S.M. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc. Natl. Acad. Sci. 2011, 108:3630-3635.
185. Silva V.A., Polesskaya A., Sousa T.A., Corrêa V.M., André N.D., Reis R.I., Kettelhut I.C., Harel-Bellan A., De Lucca F.L. Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol. Vis. 2011, 17:2228-2240.
186. Song S.H., Han S.W., Bang Y.J. Epigenetic-based therapies in cancer: progress to date. Drugs 2011, 71:2391-2403.
187. Sorbinil Retinopathy Trial Research Group Arandomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol. 1990, 108:1234-1244.
188. Spadea L., Balestrazzi E. Treatment of vascular retinopathies with Pycnogenol. Phytother. Res. 2001, 15:219-223.
189. Stankov K., Benc D., Draskovic D. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013, 132:1112-1122.
190. Sterns J.D., Smith C.B., Steele J.R., Stevenson K.L., Gallicano G.I. Epigenetics and type II diabetes mellitus: underlying mechanisms of prenatal predisposition. Front. Cell Dev. Biol. 2014, 2:15.
191. Stitt A.W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp. Mol. Pathol. 2003, 75:95-108.
192. Stitt A.W. AGEs and diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2010, 51:4867-4874.
193. Stuart J.A., Brown M.F. Mitochondrial DNA maintenance and bioenergetics. Biochim. Biophys. Acta 2006, 1757:79-89.
194. Sugawara R., Hikichi T., Kitaya N., Mori F., Nagaoka T., Yoshida A., Szabo C. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr. Eye Res. 2004, 29.
195. Syreeni A., El-Osta A., Forsblom C., Sandholm N., Parkkonen M., Tarnow L., Parving H.H., McKnight A.J., Maxwell A.P., Cooper M.E. Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes 2011, 60:3073-3080.
196. Szwergold B.S., Kappler F., Brown T.R. Identification of fructose 3-phosphate in the lens of diabetic rats. Science 1990, 247:451-454.
197. Tewari S., Santos J.M., Kowluru R.A. Damaged mitochondrial DNA replication system and the development of diabetic retinopathy. Antioxid. Redox Signal. 2012, 17:492-504.
198. Tewari S., Zhong Q., Santos J.M., Kowluru R.A. Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2012, 53:4881-4888.
199. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. 1998, 44:1013-1023.
200. Tomasetti M., Nocchi L., Staffolani S., Manzella N., Amati M., Goodwin J., Kluckova K., Nguyen M., Strafella E., Bajzikova M., Peterka M., Lettlova S., Truksa J., Lee W., Dong L.F., Santarelli L., Neuzil J. MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function. Antioxid. Redox Signal. 2014, 21:2109-2125.
201. Trudeau K., Molina A.J., Guo W., Roy S. High glucose disrupts mitochondrial morphology in retinal endothelial cells: implications for diabetic retinopathy. Am. J. Pathol. 2010, 177:447-455.
202. Turrens J.F. Mitochondrial formation of reactive oxygen species. J.Physiol. 2003, 552:335-344.
203. UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853.
204. Unger R.H. Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA 2008, 299:1185-1187.
205. Valinluck V., Tsai H.H., Rogstad D.K., Burdzy A., Bird A., Sowers L.C. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004, 32:4100-4108.
206. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
207. Van Houten B., Woshner V., Santos J.H. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair 2005, 5:145-152.
208. Vassilakopoulos T., Karatza M.-H., Katsaounou P., Kollintza A., Zakynthinos S., Roussos C. Antioxidants attenuate the plasma cytokine response to exercise in humans. J.Appl. Physiol. 2003, 94:1025-1032.
209. Villeneuve L.M., Reddy M.A., Lanting L.L., Wang M., Meng L., Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl. Acad. Sci. 2008, 105:9047-9052.
210. Vinores S.A., Campochiaro P.A., Williams E.H., May E.E., Green W.R., Sorenson R.L. Aldose reductase expression in human diabetic retina and retinal pigment epithelium. Diabetes 1988, 37:1658-1664.
211. Wakabayashi T., Hidaka R., Fujimaki S., Asashima M., Kuwabara T. MicroRNAs and epigenetics in adult neurogenesis. Adv. Genet. 2014, 86:27-44.
212. Wang J., Wu Z., Li D., Li N., Dindot S.V., Satterfield M.C., Bazer F.W., Wu G. Nutrition, epigenetics, and metabolic syndrome. Antioxid. Redox Signal. 2012, 17:282-301.
213. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence. Diabetes Res. Clin. Pract. 2011, 94:311-321.
214. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
215. Xia P., Inoguchi T., Kern T.S., Engerman R.L., Oates P.J., King G.L. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes 1994, 43:1122-1129.
216. Xue M., Qian Q., Adaikalakoteswari A., Rabbani N., Babaei-Jadidi R., Thornalley P.J. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008, 57:2809-2817.
217. Yau J.W., Rogers S.L., Kawasaki R., Lamoureux E.L., Kowalski J.W., Bek T., Chen S.J., Dekker J.M., Fletcher A., Grauslund J., Haffner S., Hamman R.F., Ikram M.K., Kayama T., Klein B.E., Klein R., Krishnaiah S., Mayurasakorn K., O'Hare J.P., Orchard T.J., Porta M., Rema M., Roy M.S., Sharma T., Shaw J., Taylor H., Tielsch J.M., Varma R., Wang J.J., Wang N., West S., Xu L., Yasuda M., Zhang X., Mitchell P., Wong T.Y. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012, 35:556-564.
218. Yokoyama I., Negita M., Liu D.G., Nagasaka T., Kobayashi T., Hayakawa A., Hayashi S., Nakao A. Prevention of free-radical induced apoptosis by induction of human recombinant Cu, Zn-SOD in pig endothelial cells. Transpl. Int. 2002, 15:220-225.
219. Young T.A., Cunningham C.C., Bailey S.M. Reactive oxygen species production by the mitochondrial respiratory chain in isolated rat hepatocytes and liver mitochondria: studies using myxothiazol. Arch. Biochem. Biophys. 2002, 405:65-72.
220. Zhang P., Huang B., Xu X., Sessa W.C. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem. Biophys. Res. Commun. 2013, 437:368-373.
221. Zheng L., Szabo C., Kern T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004, 53:2960-2967.
222. Zhong Q., Kowluru R.A. Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon. J.Cell. Biochem. 2010, 110:1306-1313.
223. Zhong Q., Kowluru R.A. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Investig. Ophthalmol. Vis. Sci. 2011, 52:8739-8746.
224. Zhong Q., Kowluru R.A. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011, 60:1304-1313.
225. Zhong Q., Kowluru R.A. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Investig. Ophthalmol. Vis. Sci. 2013, 54:244-250.
226. Zhong Q., Kowluru R.A. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 2013, 62:2559-2568.
227. Zhong Q., Mishra M., Kowluru R.A. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54:3941-3948.
228. Zhu J.K. Active DNA demethylation mediated by DNA glycosylases. Annu. Rev. Genet. 2009, 43:143-166.
229. Ziech D., Franco R., Pappa A., Panayiotidis M.I. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat. Res. 2011, 711:167-173.